Proprietary Tools & Products
Faster delivery. Richer insight. Strategy that delivers.
Most research firms use the same tools for every project. We built our own because the questions pharma and biotech brands face don't always fit standard methods.
Level 5 Intelligence combines AI-powered tools with our researchers' expertise to move faster, go deeper, and deliver findings that are ready for commercial decisions, not just insights reviews.
Level 5 Intelligence:
Rare Pulse — Patient and Caregiver Insights, Fast
When you need to hear from the rare community quickly and confidently, Level 5 delivers. In partnership with Rare360, we close the gap between when you need insight and when you get it. Rare Pulse delivers decision-ready insight from rare patient and caregiver communities in 2-3 weeks, not 2-3 months.
QUIN (Query-based Intelligence Navigator) - Patient Journey Intelligence
Traditional journey interviews take time and leave gaps. QUIN is an AI agent that enhances patient journey interviews in real time by increasing precision, reducing fieldwork time, and surfacing the strategic details that usually get lost in synthesis.
ECHO (Enhanced Communication & Human Optimization) - Message Optimization
Your messaging either lands or it doesn't and finding out late is expensive. ECHO tests and refines brand messaging in live conversations using AI pattern recognition, identifying in real time what's clear, what's credible, and what's falling flat.
VERA (Values-Embedded Reasoning Architecture) - Behavioral Science to Brand Strategy
Knowing why healthcare stakeholders behave the way they do is one thing. Knowing what to do about it is another. VERA translates behavioral science insights into specific, actionable marketing levers helping brand teams drive sustained HCP engagement and patient loyalty, not just awareness.
Clinical Trials Insights - Launch Intelligence Before the Data Is Public
The brands that win at launch don't wait for published trial data to start planning. Level 5's proprietary Clinical Trials Insights methodology engages trial subjects, caregivers, investigators, and coordinators during the investigational phase, surfacing real experience with the drug before it hits the market. The result: launch strategies built on early insights, not assumptions.
“The collaboration and the partnership have just been phenomenal. When you work with them it feels like they’re in it with you.”